A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Relapsing Multiple Sclerosis · Secondary Progressive Multiple Sclerosis · Progressive Relapsing Multiple Sclerosis
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 2,500 (planned)
- Started
- Apr 16, 2024
- Main results expected
- Apr 30, 2029
- Fully finished
- Apr 30, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and AEs leading to permanent study intervention discontinuation
Measured over: From baseline until the End of study approximately 4 years per participant
Number of Participants with Potentially clinically significant abnormalities (PCSAs)
Measured over: From baseline until the End of study approximately 4 years per participant
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06372145 · record last updated 2026-08-17 · checked 2026-11-09 15:47 UTC